Cocktail of chemotherapy drugs may be safe, effective for patients with metastatic pancreatic cancer

Pancreatic cancer carries a poor prognosis, and it often goes undetected until advanced stages. A new BJS (British Journal of Surgery) study indicates that a certain cocktail of chemotherapy drugs may be a safe and effective treatment option for patients with a metastatic form of the disease.

The study, which was an early-phase 46-patient trial intended to provide preliminary results regarding safety and efficacy, tested a strategy involving injections of paclitaxel into the abdomen and injections of gemcitabine and nab-paclitaxel (a combination of paclitaxel and a protein called albumin) into the blood.

The treatment had acceptable toxicities, and patients had a median survival time of 14.5 months, with a 1-year survival rate of 60.9%.

Now, a phase 3 study to compare survival outcomes between this therapy and standard chemotherapy has been launched."

Sohei Satoi, MD, Senior Author, Kansai Medical University, in Japan

Source:
Journal reference:

Yamada, S., et al. (2020) Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. BJS. doi.org/10.1002/bjs.11792.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
How AI is advancing mammographic density-based breast cancer risk prediction